Serum androgens and prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 5, Issue 8, 1996, Pages 621-625

  Nomura, Abraham M Y ^a   Stemmermann, Grant N ^b   Chyou, Po Huang ^c   Henderson, Brian E ^d   Stanczyk, Frank Z ^d  

^a KUAKINI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MARSHFIELD CLINIC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIONE; ANDROSTERONE DERIVATIVE; TESTOSTERONE;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; DISEASE ASSOCIATION; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; ANDROGENS; ASIAN AMERICANS; CASE-CONTROL STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0029790167     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. American Cancer Society. Cancer Facts and Figures - 1996, p. 7. Atlanta, GA: American Cancer Society, 1996.
2. Henderson, B. E., Ross, R. K., Pike, M. C., and Casagrande, J. T. Endogenous hormones as a major factor in human cancer. Cancer Res., 42: 3232-3239, 1982.
3. Wilson, J. D. Recent studies on the mechanism of action of testosterone. N. Engl. J. Med., 287: 1284-1291, 1972.
4. Grino, P. B., Griffin, J. E., and Wilson, J. D. Testosterone at high concentration interacts with the human androgen receptor similar to dihydrotestosterone. Endocrinology, 126: 1165-1172, 1988.
5. Coffey, D. S. Androgen action and the sex accessory tissues. In: E. Knobil, J. D. Neill, and L. L. Ewing (eds.), The Physiology of Reproduction, pp. 1081-1118. New York: Raven Press, 1988.
6. Ross, R. K., Bernstein, L., Lobo, R. A., Shimizu, H., Stanczyk, F. Z., Pike, M. C., and Henderson B. E. 5-α-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339: 887-889, 1992.
7. Brawley, O. W., Ford, L. G., Thompson, I., Perlman, J. A., and Kramer, B. S. 5-a-Reductase inhibition and prostate cancer prevention. Cancer Epidemiol., Biomarkers & Prev., 3: 177-182, 1994.
8. Brawer, M. K., and Ellis, W. J. Chemoprevention for prostate cancer. Cancer (Phila.), 75: 1783-1789, 1995.
9. Waterhouse, J., Muir, C., Correa, P., and Powell, J. (eds.). Cancer Incidence in Five Continents, Vol. III. IARC Scientific Publ. No. 15. Lyon, France: IARC, 1976.
10. Parkin, D. M., Muir, C. S., Whelan, S. L., Gao, Y-T., and Ferlay, J., Powell, J. (eds.). Cancer Incidence in Five Continents, Vol. VI. IARC Scientific Publ. No. 120. Lyon, France: IARC, 1992.
11. Kagan, A., Harris, B. R., Winkelstein, W., Jr., Johnson, K. G., Kato, H., Syme, S., Rhoads, G. G., Gay, M. L., Nichaman, M. Z., Hamilton, H. B., and Tillotson, J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J. Chronic Dis., 27: 345-364, 1974.
12. Goebelsmann, U., Arce, J. J., Thorneycroft, I. H., and Mishell, D. R., Jr. Serum testosterone concentrations in women throughout the menstrual cycle and following hCG administration. Am. J. Obstet. Gynecol., 119: 445-452, 1974.
13. Serafine, P., Ablan, F., and Lobo, R. A. 5-α-Reductase activity in the genital skin of hirsute women. J. Clin. Endocrinol. & Metab., 60: 349-355, 1985.
14. Thorneycroft, I. H., Ribeiro, W. O., Stone, S., and Tillson, S. A. A radio-immunoassay of androstenedione. Steroids, 21: 111-122, 1973.
15. Wong, I. L., Morris, R. S., Chang, L., Apahn, M-A., Stanczyk, F. Z., and Lobo, R. A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. & Metab., 80: 233-238, 1995.
16. Matteri, R. K., Stanczyk, F. Z., Gentzschein, E. E., Delgado, C., and Lobo, R. A. Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with polycyctic ovarian syndrome. Am. J. Obstet. Gynecol., 161: 1704-1709, 1989.
17. Lobo, R. A., and Kletzky, O. A. Normalization of androgen and sex hormone-binding globulin levels after treatment of hyperprolactinemia. J. Clin. Endocrinol. & Metab., 56: 562-566, 1982.
18. Freund, R. J., and Littell, R. C. Statistical Analysis System (SAS) for Linear Models. Cary, NC: SAS Institute, Inc., 1981.
19. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research. The Analysis of Case-Control Studies, Vol. 1, pp. 164-166, 247-276. IARC Scientific Publ. No. 32. Lyon, France: IARC, 1980.
20. Harrell, F. E., Jr. The PHGLM procedure. In: S. P. Joyner (ed.), SUGI Supplemental Library User's Guide, pp. 267-294. Cary, NC: SAS Institute, Inc., 1983.
21. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research. The Design and Analysis of Cohort Studies, Vol II, pp. 297-300.. IARC Scientific Publ. No. 82. Lyon, France: IARC, 1987.
22. de Lacerda, L., Kowarski, A., Johanson, A. J., Athanasiou, R., and Migeon, C. J. Integrated concentration and circadian variation of plasma testosterone in normal men. J. Clin. Endocrinol. & Metab., 37: 366-371, 1973.
23. Van Cauter, E., and Turek, F. W. Endocrine and other biological rhythms. In: L. J. DeGroot, M. Bessar, H. G. Burger, J. K. Jameson, D. L. Loriaux, J. C. Marshall, W. D. Odell, J. T. Putts, Jr., and A. H. Rubenstein (eds.), Endocrinology, pp. 2487-2548. Philadelphia: W. B. Saunders Co., 1995.
24. Barrett-Connor, E., Garland, C., McPhillips, J. B., Khaw, K-T., and Wingard, D. L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res., 50; 169-173, 1990.
25. Nomura, A., Heilbrun, L. K., Stemmermann, G. N., and Judd, H. L. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res., 48: 3515-3517, 1988.
26. Hsing, A. W., and Comstock, G. W. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol., Biomarkers & Prev., 2: 27-32, 1993.
27. Ahluwalia, B., Jackson, M. A., Jones, G. W., Williams, A. O., Rao, M. S., and Raiguru, S. Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations. Cancer (Phila.), 48: 2267-2273, 1981.
28. Ghanadian, R., Puah, C. M., and O'Donoghue, E. P. N. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br. J. Cancer, 39: 696-699, 1979.
29. Hill, P., Wynder, E. L., Barbaczewski, L., and Walker, A. R. P. Effect of diet on plasma and urinary hormones in South African black men with prostatic cancer. Cancer Res., 42: 3864-3869, 1982.
30. Meikle, A. W., Smith, J. A., and West, D. W. Familial factors affecting prostate cancer risk and plasma sex-steroid levels. Prostate, 6: 121-128, 1985.
31. Zumoff, B., Evin, J., Strain, G. W., Rosenfeld, R. S., O'Connor, J., Freed, S. Z., Kream, J., Whitmore, W. S., Fukushima, D. K., and Hellman, L. Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a "two-disease" theory. Prostate, 3: 579-588, 1982.
32. Hammond, G. L., Kontturi, M., Vihko, P., and Vihko, R. Serum steroids in normal males and patients with prostatic diseases. Clin. Endocrinol., 9: 113-121, 1978.
33. Hobisch, A., Cullig, Z., Radmayr, C., Bartsch, G., Klocker, H., and Hittmair, A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res., 55: 3068-3072, 1995.
34. Pertschuk, L. P., Schaeffer, H., Feldman, J. G., Macchia, R. J., Kim, Y-D., Eisenberg, K., Braithwaite, L. V., Axiotis, C. A., Prins, G., and Greene, G. L. Immunostaining for prostate cancer androgen receptor in paraffin !dentines a subset of men with a poor prognosis. Lab. Invest., 73: 302-305, 1995.
35. Irvine, R. A., Yu, M. C., Ross, R. K., and Coetzee, G. H. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res., 55: 1937-1940, 1995.